Johnson & Johnson has agreed to acquire Ollin Biosciences for $2.2 billion upfront, adding a late-stage investigational treatment for retinal vascular diseases to its ophthalmology pipeline.
The transaction also includes the potential for approximately $1.125 billion in additional regulatory and commercial milestone payments.
Ollin is developing OLN324, a Phase 3 investigational bispecific antibody designed to target vascular endothelial growth factor and angiopoietin-2, two pathways involved in retinal disease.
The therapy is being developed for conditions including wet age-related macular degeneration and diabetic macular edema, which together affect more than 40 million people worldwide.
Johnson & Johnson said OLN324 combines high Ang2 potency with a small protein format known as a minibody that could enable improved control of retinal fluid.
The company believes the treatment could potentially produce stronger and more sustained disease control while allowing more time between treatments.
Johnson & Johnson will also enter a separate development funding agreement with Blackstone Life Sciences contingent on completion of the Ollin acquisition.
Under that agreement, Blackstone will provide a total of $750 million to Johnson & Johnson over multiple years to fully fund Phase 3 development of OLN324.
Blackstone will be eligible to receive certain regulatory and sales milestone payments along with single-digit royalties in return for the development funding.
Johnson & Johnson expects the Ollin transaction to close before the end of 2026, subject to regulatory approvals and customary closing conditions.
The acquisition would strengthen the company’s ophthalmology pipeline and build on its existing presence in vision care and eye disease.
Johnson & Johnson plans to apply its clinical development, scientific and commercial capabilities to advance OLN324 following completion of the transaction.
KEY QUOTES
“OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control. The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients.”
Kip Connor, Vice President And Ophthalmology Disease Area Stronghold Leader At Johnson & Johnson

